Detailed Information
Cited 0 time in 
Cited 2 time in 
Cited 2 time in
Metadata Downloads
Erlotinib HCL (Tarceva ®) induced radiation recall dermatitis
- Issue Date
- 2010
- Keywords
- Epidermal growth factor receptor; Erlotinib; Radiation recall dermatitis
- Citation
- Korean Journal of Dermatology, v.48, no.10, pp 872 - 875
- Pages
- 4
- Indexed
- SCOPUS
KCI
- Journal Title
- Korean Journal of Dermatology
- Volume
- 48
- Number
- 10
- Start Page
- 872
- End Page
- 875
- ISSN
- 0494-4739
- Abstract
- Erlotinib (Tarceva ®) is a new anti-cancer agent that acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell lung cancer and pancreatic cancer. A patient consulted our clinic and she had erythematous patches and vesicles on the submandibular area. She had taken erlotinib for the treatment of recurred lung cancer for 2 weeks. We report here on a case of radiation recall dermatitis that was induced by erlotinib in a 69-year-old woman who was previously irradiated on her submandibular area.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.